The goal of the trial is to evaluate the safety, tolerability and immunogenicity of the HIVconsvX vaccine -- a mosaic vaccine targeting a broad range of HIV-1 variants, making it potentially applicable for HIV strains in any geographical region.
A low number of platelets- blood cells that help prevent blood loss when vessels are damaged-can result in no symptoms or can lead to an increased risk of bleeding or, in some cases, clotting.
Two doses from either the Oxford/AstraZeneca or the Pfizer vaccine are over 80 per cent effective in preventing infection from the B1.617.2 variant of COVID-19, first discovered in India, a new UK government study has reportedly found.
Two doses of the Oxford/AstraZeneca vaccine have shown to prevent around 85 to 90 per cent of symptomatic COVID-19 infections, the first real-world data from Public Health England (PHE) has found.
Those given a first dose of either of the two vaccines currently being administered by the National Health Service (NHS) and who became infected with SARS-Cov-2 – the coronavirus which causes COVID-19 – three weeks later were between 38 and 49 per cent less likely to pass the virus on than unvaccinated people.
The IMF has projected an impressive 12.5 per cent growth rate for India in 2021, while S&P Global Ratings has said the Indian economy is projected to grow at 11 per cent in the current fiscal
The Oxford–AstraZeneca Covid-19 vaccine, a version of which is also being used in India, is made from an adenovirus isolated from chimpanzee poop, which has been genetically changed so that it is impossible for it to grow in humans.
Chen added that in the UK, a high proportion of patients have long Covid-19, but reasons for this phenomenon is not clear so far.
The government on Monday revised the interval between two doses of Oxford-AstraZeneca's Covishield vaccine.
The COVID-19 vaccine developed by Oxford University and bio-pharmaceutical major AstraZeneca is safe and works extremely well, UK Prime Minister Boris Johnson said on Tuesday, amid reports that the doses were causing blood clot-related complications.
Data suggests that in the over 80s, a single dose of either vaccine is more than 80 per cent effective at preventing hospitalisation, around 3 to 4 weeks after the jab, PHE said in a statement.
Just one vaccine shot reduces the risk of being hospitalised by Covid-19 by more than 90 per cent, according to new findings, Daily Mail reported.
A three-month interval between doses of the Oxford COVID-19 vaccine results in higher vaccine efficacy than a six-week gap, according to a new study which says the first dose can offer up to 76 per cent protection in the months between the two jabs.
The University of Oxford has launched the first study to assess the safety and immune responses in children and young adults of its coronavirus vaccine.
The COVID-19 vaccine developed by Oxford University and produced by AstraZeneca has shown efficacy against the UK variant of the coronavirus, according to an ongoing study by researchers.
'Aatmanirbharta' implying self-reliance has been named by Oxford Languages as its Hindi word of the year 2020 as it "validated the day-to-day achievements of the countless Indians who dealt with and survived the perils of a pandemic".
The dosing mishap was presented to the trial participants in a letter dated June 8 as an opportunity for University of Oxford researchers to learn how well the vaccine works at different doses. The letter was signed by the trial's chief investigator, Oxford professor Andrew J. Pollard
Poonawalla'' remarks came soon after after India's drugs regulator, Drug Controller General of India (DCGI) approved Covishield for restricted emergency use.
An expert panel on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) on Friday recommended to grant emergency use authorisation for the Oxford COVID-19 vaccine Covishield, being manufactured by Serum Institute of India, sources said on Friday.
Top News
Latest News
